Vor Biopharma Inc. (VOR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $19.00K; Additional Paid in Capital, Common StockUSD $1.24B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-922.00K; Retained Earnings (Accumulated Deficit)USD $-1.44B.
- 2026-03-31: Common Stock, Value, IssuedUSD $19.00K; Additional Paid in Capital, Common StockUSD $1.22B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-706.00K; Retained Earnings (Accumulated Deficit)USD $-1.37B.
- 2025-12-31: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $988.60M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $41.00K; Retained Earnings (Accumulated Deficit)USD $-1.15B.
- 2025-09-30: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in Capital, Common StockUSD $650.32M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $12.00K; Retained Earnings (Accumulated Deficit)USD $-2.88B.
Vor Biopharma Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.00K | $1.24B | $-922.00K | $-1.44B | $-200.20M | 3 month · $9.40M | (m) |
| 2026-03-31 | $19.00K | $1.22B | $-706.00K | $-1.37B | $-150.42M | 3 month · $8.87M | (m) |
| 2025-12-31 | $18.00K | $988.60M | $41.00K | $-1.15B | $-164.31M | 12 month · $18.91M | (m) |
| 2025-09-30 | $15.00K | $650.32M | $12.00K | $-2.88B | $-2.23B | 3 month · $8.03M | (m) |
| 2025-06-30 | $13.00K | $557.42M | $14.00K | $-2.06B | $-1.51B | 3 month · $1.84M | (m) |
| 2025-03-31 | $13.00K | $555.51M | $23.00K | $-489.48M | $66.07M | 3 month · $1.93M | (m) |
| 2024-12-31 | $13.00K | $553.62M | $22.00K | $-456.99M | $96.66M | 12 month · $9.85M | (m) |
| 2024-09-30 | $7.00K | $499.16M | $68.00K | $-426.28M | $72.95M | 3 month · $2.26M | (m) |
| 2024-06-30 | $7.00K | $496.87M | $-70.00K | $-398.72M | $98.08M | 3 month · $2.79M | (m) |
| 2024-03-31 | $7.00K | $494.00M | $-87.00K | $-370.88M | $123.03M | 3 month · $3.08M | (m) |
| 2023-12-31 | $7.00K | $490.87M | $-77.00K | $-340.08M | $150.72M | 12 month · $13.36M | (m) |
| 2023-09-30 | $7.00K | $488.87M | $-280.00K | $-313.82M | $174.78M | 3 month · $3.16M | (m) |
| 2023-06-30 | $7.00K | $485.51M | $-436.00K | $-280.63M | $204.45M | 3 month · $4.24M | (m) |
| 2023-03-31 | $7.00K | $481.03M | $-174.00K | $-250.65M | $230.22M | 3 month · $4.07M | (m) |
| 2022-12-31 | $7.00K | $473.59M | $-770.00K | $-222.22M | $250.61M | 12 month · $10.70M | (m) |
| 2022-09-30 | $4.00K | $358.21M | $-1.18M | $-198.31M | $158.73M | 3 month · $3.33M | (m) |
| 2022-06-30 | $4.00K | $350.81M | $-1.33M | $-174.52M | $174.97M | 3 month · $1.74M | (m) |
| 2022-03-31 | $4.00K | $348.38M | $-1.07M | $-152.86M | $194.45M | 3 month · $1.75M | (m) |
| 2021-12-31 | $4.00K | $346.38M | (m) | $-130.12M | $216.26M | 12 month · $4.31M | 12 month · $17.13M |
| 2021-09-30 | $4.00K | $344.82M | (m) | $-111.87M | $232.96M | 3 month · $1.15M | (m) |
| 2021-06-30 | $4.00K | $343.42M | (m) | $-93.32M | $250.11M | 3 month · $1.07M | (m) |
| 2021-03-31 | $4.00K | $342.13M | (m) | $-74.95M | $267.19M | 3 month · $891.00K | 3 month · $17.13M |
| 2020-12-31 | $1.00K | $2.16M | (m) | $-61.22M | $-59.06M | 12 month · $1.34M | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-44.14M | 3 month · $483.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-32.99M | 3 month · $153.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-25.12M | 3 month · $112.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-17.43M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |